Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia
Open Access
- 26 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 35 (1), 51-60
- https://doi.org/10.1007/s10557-020-07058-x
Abstract
Purpose Hyperuricemia carries an increased risk of atherothrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). This may at least in part be due to inadequate P2Y12 inhibition. The aim of this study was to prospectively investigate the potential association between hyperuricemia and decreased platelet inhibition by P2Y12 antagonists. Methods Levels of uric acid as well as on-treatment residual platelet reactivity in response to adenosine diphosphate (ADP) were assessed in 301 clopidogrel-treated patients undergoing elective angioplasty and stenting, and in 206 prasugrel- (n = 118) or ticagrelor-treated (n = 88) ACS patients following acute PCI. Cut-off values for high on-treatment residual ADP-inducible platelet reactivity (HRPR) were based on previous studies showing an association of test results with clinical outcomes. Results Hyperuricemia was significantly associated with increased on-treatment residual ADP-inducible platelet reactivity in clopidogrel- and prasugrel-treated patients in univariate analyses and after adjustment for differences in patient characteristics by multivariate regression analyses. In contrast, ticagrelor-treated patients without and with hyperuricemia showed similar levels of on-treatment residual platelet reactivity to ADP. HRPR occurred more frequently in clopidogrel- and prasugrel-treated patients with hyperuricemia than in those with normal uric acid levels. In contrast, hyperuricemic patients receiving ticagrelor did not have a higher risk of HRPR compared with those with normal uric acid levels. Conclusion Hyperuricemia is associated with decreased platelet inhibition by thienopyridines but a normal response to ticagrelor. It remains to be established if lowering uric acid increases the antiplatelet effects of clopidogrel and prasugrel in hyperuricemic patients with HRPR.Keywords
Funding Information
- Medical Scientific Fund of the Mayor of the City of Vienna (14016)
- Oesterreichische Nationalbank (16155)
This publication has 35 references indexed in Scilit:
- Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregationJournal of Thrombosis and Haemostasis, 2009
- Uric Acid and Cardiovascular RiskThe New England Journal of Medicine, 2008
- Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemiaAmerican Journal of Physiology-Renal Physiology, 2008
- Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patientsEuropean Heart Journal, 2008
- Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantationEuropean Heart Journal, 2006
- Uric acid and inflammatory markersEuropean Heart Journal, 2006
- Multiple electrode aggregometry: A new device to measure platelet aggregation in whole bloodThrombosis and Haemostasis, 2006
- Soluble CD40LCirculation, 2003
- Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells Via Mitogen-Activated Protein Kinase and Cyclooxygenase-2Hypertension, 2003
- Urate predicts subsequent cardiac death in stroke survivorsEuropean Heart Journal, 2002